Mon, February 23, 2009
[ Mon, Feb 23rd 2009 ]: Market Wire
Amedisys to Host Investor Day
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ]: Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009
Tue, February 17, 2009
Mon, February 16, 2009
Fri, February 13, 2009
Thu, February 12, 2009
Wed, February 11, 2009
Tue, February 10, 2009
Mon, February 9, 2009
Sun, February 8, 2009
Fri, February 6, 2009
Thu, February 5, 2009

La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial


  Copy link into your clipboard //health-fitness.news-articles.net/content/2009/ .. cy-analysis-for-riquent-phase-3-aspen-trial.html
  Print publication without navigation Published in Health and Fitness on , Last Modified on 2009-02-12 04:54:47 by Market Wire
          🞛 This publication is a summary or evaluation of another publication

SAN DIEGO--([ BUSINESS WIRE ])--La Jolla Pharmaceutical Company (Nasdaq:LJPC) announced today that the Independent Data Monitoring Board for the Riquent® Phase 3 ASPEN study has informed the Company that they have completed the first interim efficacy analysis and determined that continuing the study is futile. The Company has decided to stop the study, unblind the data and evaluate the results. The Company expects to provide additional guidance on its strategic options going forward in the near future.


Publication Contributing Sources

Similar Health and Fitness Publications